Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals offers funding for independent research and educational projects advancing science and care in cystic fibrosis, pain, IgA nephropathy, beta thalassemia, sickle cell disease, and other priority diseases.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | 2026 (next cycle for Circle of Care, RIA, VIA awards)
Funding Amounts: No set cap for most grants; CF Research Innovation Awards: up to $750,000 over 3 years; VIA: up to $750,000/project; Mentored RIA: up to $125,000 over 2 years
Summary: Supports independent research, educational initiatives, and sponsorships advancing knowledge and care in cystic fibrosis and other Vertex-priority diseases.
Key Information: Rolling submissions for most areas; specific RFP cycles for beta thalassemia and sickle cell disease; overhead generally capped at 35%.
Description
Vertex Pharmaceuticals offers a comprehensive funding portfolio including Investigator Sponsored Studies (ISS), independent medical education grants, patient education/advocacy grants, and sponsorships. The primary focus is on advancing research and knowledge in cystic fibrosis (CF), pain, IgA nephropathy (IgAN), beta thalassemia, sickle cell disease, and other Vertex-priority disease areas. Funding is available for independent research, educational programs, and events that align with Vertex’s scientific and clinical interests. Special competitive programs—such as the Circle of Care, Research Innovation Awards (RIA), and Vertex Innovation Awards (VIA)—specifically target CF research and community support.
